As the cure rates for haematological malignancies have improved, the exploration of the
balance between efficacy and side effects has become a major research target. The …

Pharmacogenetics represents an exciting, new promising tool for the individualisation of
therapy. Several genetic polymorphisms and haplotypes have been considered in an …

Methotrexate is a folate analog that is used in the treatment of cancers (eg acute
lymphoblastic leukemia, non-Hodgkin lymphoma, osteosarcoma, and colon cancer) and …

Background Methotrexate (MTX) is an important component of the therapy for childhood
acute lymphoblastic leukemia. Treatment with high‐dose MTX often causes toxicity …

Acute lymphoblastic leukaemia (ALL) is a prevalent form of pediatric cancer that accounts for
70–80% of all leukemias. Genome-based analysis, exome sequencing, transcriptomics and …

Methotrexate (MTX) is an important component of therapy used to treat childhood acute
lymphoblastic leukemia (ALL). Two single-nucleotide polymorphisms (SNPs) in the …

Background The aim of this study is to analyze polymorphisms in genes involved in 6-
mercaptopurine detoxification (TPMT); methotrexate (MTX) metabolism including ABCB1 (or …

Aim: Pharmacogenetics of methotrexate (MTX) contributes to interindividual differences in
toxicity. We aimed to evaluate the impact of SNPs within the MTX pathway genes on MTX …

Background The antifolate agent methotrexate is an important component of maintenance
therapy in acute lymphoblastic leukemia, although methotrexate-related toxicity is often a …

The associations between methylenetetrahydrofolate reductase (MTHFR) polymorphism
and methotrexate (MTX)-induced toxicities in patients with acute lymphoblastic leukemia …